In the present study, PD-L1 expression in the tumor was associated with PFS and objective response, indicating that ICIs should not be thoroughly excluded from candidate therapeutic strategies for NSCLC patients with EGFR mutation or ALK fusion, especially in cases with high PD-L1 expression. The gene discussed is EGFR; the disease is neoplasm.